Researchers get clear picture of cancer growth factor
20 September, 2002 by Graeme O'NeillThe crystal ball has cleared, and a Melbourne research team has seen one of the shapes of the future in cancer research, after solving the elusive structure of a receptor for a growth factor involved in many common cancers.
Researchers assessing AustCancer Phase II vaccine trial
19 September, 2002 by Graeme O'NeillPerth-based cancer therapeutics company Australian Cancer Technology announced today that researchers at St Vincent's Hospital, Sydney have begun analysing results from the first group of patients in its Phase Ib/IIa clinical trial of its Pentrix vaccine for common cancers.
Two-for-one gastric research result - plus a bonus
13 September, 2002 by Graeme O'NeillTake one gene, introduce two different mutations, and reproduce the symptoms of two major diseases of the digestive tract: gastric cancer and inflammatory bowel disease. And in addition to that two-for-one result, Assoc Prof Andy Giraud of Melbourne University (Western Hospital) and Dr Matthias Ernst of the Ludwig Institute for Cancer Research have convicted a suspect gene that their US and Japanese peers had previously exonerated.
Panbio finds R&D leader in its own backyard
05 September, 2002 by Pete YoungMedical diagnostics company Panbio has headhunted Prof Stuart Hazell, dean of the University of Southern Queensland's science faculty, as its vice-president for R&D.
Griffith, Monash researchers behind new start-up
04 September, 2002 by Pete YoungTwo leading Australian scientists - Prof Mark von Itzstein and Prof Ross Coppel - have helped form a new company to deliver novel pharmaceuticals for use against drug-resistant bacteria.
Monash IRD creates mouse model for neuro disease
04 September, 2002 by Melissa TrudingerResearchers at the Monash Institute of Reproduction and Development have succeeded in creating a transgenic mouse model for Kennedy disease, a neurodegenerative disease that affects approximately 1 in 50,000 men.
Autogen presents diabetes findings at Brazil conference
29 August, 2002 by Melissa TrudingerThe discovery of a gene that links type 2 diabetes and heart disease could lead to the development of new therapeutic treatments for diabetes, according to Victorian biotech Autogen.
Good results boost AustCancer breast cancer program
28 August, 2002 by Melissa TrudingerWA-headquartered Australian Cancer Technology has accelerated its breast cancer therapeutic program after reporting good first-stage results.
$118m for institutes in NHMRC program grants
28 August, 2002 by Melissa TrudingerSixteen National Health and Medical Research Council program grants worth more than $118 million have been awarded to research teams at some of Australia's top research institutions.
Metabolic nets BIF grant for pre-clinical studies
23 August, 2002 by Melissa TrudingerMelbourne company Metabolic Pharmaceuticals has received a BIF grant of $234,700 to pursue pre-clinical studies on an orally available iron-chelating compound.
Malaria vaccine breakthrough for WEHI
15 August, 2002 by Melissa TrudingerGroundbreaking research on a malaria toxin could lead to the development of an effective vaccine for the deadly disease according to a paper published in the August 15 issue of Nature.
Papillomavirus vaccine looking positive after Phase I
14 August, 2002 by Pete YoungPromising results have emerged from a two-year Phase I human clinical trial of an Australian-developed therapeutic vaccine targeting cervical cancer.
Cell death key discovered by Monash Institute
07 August, 2002 by Tanya HollisMelbourne researchers have uncovered a new genetic player in programmed cell death, offering a fresh target for potential cancer therapies.
Monash researchers in osteoporosis find
06 August, 2002 by Tanya HollisAn international collaboration including Melbourne researchers has uncovered two reasons for calcium deposits in bones and joints, setting the foundation for new osteoporosis therapies.
Starpharma gains new US patent approval
05 August, 2002 by Tanya HollisNanotechnology drug developer Starpharma Pooled Development today announced it had gained approval for a United States patent over its dendrimer-based anti-cancer products.
